Clinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors.

For the treatment of congestive heart failure and hypertension.

For the treatment of premature ejaculation.

For the treatment of symptoms associated with irritable bowel syndrome.

For use in combination treatment of HIV infection (AIDS).

For the treatment of HIV-1 infection in combination with other antiretroviral agents.

Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.

For the treatment of pain.

For the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis.

For topical treatment of psoriasis and psoriatic disorders.

For the treatment of Alzheimer's disease (AD).

For the treatment of solid tumors.

For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.

For the treatment of neovascular (wet) age-related macular degeneration.

Milnacipran is used to treat moderate to severe clinical depression but this indication is not yet FDA-approved in the USA. Milnacipran is labelled for the treatment of ...

Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

For the treatment of acute deep vein thrombosis.

For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.

Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to ...

Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.